Mezilamine, a new dopamine antagonist, blocks presynaptic but stimulates postsynaptic alpha-adrenoceptors.
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism; D018492:Dopamine Antagonists; D004347:Drug Interactions; D005260:Female; D009119:Muscle Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D013116:Spinal Cord / Q000502:physiology; D013569:Synapses / Q000187:drug effects*; D013574:Synaptosomes / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D018492:Dopamine Antagonists; D010879:Piperazines; D011743:Pyrimidines; C014287:mezilamine; D009638:Norepinephrine